Search

Displaying results 2561 - 2570 of 8517 in total
  1. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired

  2. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). … A letter of non-approval for parecoxib was issued by the FDA in 2005.

    Products: PARECOXB parecoxib (as sodium) 40mg powder for solution for injection
  3. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

  4. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.

  5. Drug

    Cefpiramide

    go.drugbank.com/drugs/DB00430
    Approved

    Cefpiramide is a third-generation cephalosporin antibiotic.

  6. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities such as hypertension, diabetes, and depression. … [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].

  7. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  8. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    [L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755] … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of

  9. Drug

    Zinc chloride

    go.drugbank.com/drugs/DB14533
    Approved

    [L14189] Zinc chloride was granted FDA approval before 26 June 1986.[L14189]

  10. Drug

    Alfimeprase

    go.drugbank.com/drugs/DB04919
    Investigational

    Alfimeprase is a recombinant analog of fibrolase. Fibrolase is a zinc-containing metalloproteinase isolated from the venom of the southern copperhead snake (Agkistrodon contortrix contortrix). It is a small protein that contains 203 resi...